Pulmatrix (PULM) Research Coverage Started at HC Wainwright

Investment analysts at HC Wainwright started coverage on shares of Pulmatrix (NASDAQ:PULM) in a research note issued to investors on Friday, The Fly reports. The firm set a “buy” rating on the biotechnology company’s stock.

Separately, ValuEngine upgraded shares of Pulmatrix from a “strong sell” rating to a “sell” rating in a report on Friday, February 2nd.

Shares of Pulmatrix (NASDAQ PULM) opened at $1.48 on Friday. Pulmatrix has a fifty-two week low of $1.35 and a fifty-two week high of $5.34.

Pulmatrix (NASDAQ:PULM) last announced its quarterly earnings data on Thursday, November 9th. The biotechnology company reported ($0.22) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.30) by $0.08. The firm had revenue of $0.34 million during the quarter. research analysts forecast that Pulmatrix will post -1 earnings per share for the current fiscal year.

A hedge fund recently raised its stake in Pulmatrix stock. Vanguard Group Inc. grew its position in Pulmatrix Inc (NASDAQ:PULM) by 8.0% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 99,758 shares of the biotechnology company’s stock after purchasing an additional 7,351 shares during the quarter. Vanguard Group Inc. owned approximately 0.52% of Pulmatrix worth $240,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 19.95% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Pulmatrix (PULM) Research Coverage Started at HC Wainwright” was originally posted by Community Financial News and is owned by of Community Financial News. If you are accessing this piece on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.com-unik.info/2018/02/09/pulmatrix-pulm-research-coverage-started-at-hc-wainwright.html.

About Pulmatrix

Pulmatrix, Inc is a clinical stage biopharmaceutical company developing inhaled therapies to address serious pulmonary disease. The Company’s product pipeline is focused on advancing treatments for rare diseases, including PUR1900, an inhaled anti-fungal for patients with lung disease, including cystic fibrosis.

The Fly

Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit